Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Subscribe To Our Newsletter & Stay Updated
